Clinical Trials

 

Romark is conducting clinical trials of its investigational new drug candidate NT-300 (nitazoxanide extended-release tablets). NT-300 is being investigated as a broad-spectrum antiviral medicine for treating and preventing viral respiratory illnesses caused by seasonal, emerging and drug-resistant viruses, including COVID-19.
See below for additional information.

To get involved, email: medinfo@romark.com or call
877-925-4642.

Romark is among the many companies working to respond to the novel coronavirus global health emergency. Romark has initiated clinical studies of NT-300 (nitazoxanide extended-release) for both the prevention and treatment of COVID-19 and other viral respiratory illnesses.
Romark has also initiated a Phase 3 clinical trial of NT-300 (nitazoxanide extended-release tablets) for the treatment of viral respiratory illnesses caused by rhinoviruses and other enteroviruses.

NT-300 is an investigational new drug product and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities for any use. The safety and efficacy of this new product has not been established.